Have a feature idea you'd love to see implemented? Let us know!

RENB Renovaro Biosciences Inc

Price (delayed)

$1.77

Market cap

$280.93M

P/E Ratio

N/A

Dividend/share

N/A

EPS

-$0.85

Enterprise value

$284.53M

enochian biosciences (formerly dandrit biotech usa inc.) a biopharmaceutical company, focuses on the development and commercialization of novel therapies aimed to change the course of immunotherapy treatments for hiv/aids and ...

Highlights
The debt has declined by 17% year-on-year
The equity has surged by 110% year-on-year but it has declined by 26% since the previous quarter
Renovaro Biosciences's quick ratio has shrunk by 63% YoY but it has surged by 50% QoQ
Renovaro Biosciences's net income has plunged by 181% YoY and by 43% from the previous quarter
The company's EPS fell by 20% YoY

Key stats

What are the main financial stats of RENB
Market
Shares outstanding
158.72M
Market cap
$280.93M
Enterprise value
$284.53M
Valuations
Price to earnings (P/E)
N/A
Price to book (P/B)
2.66
Price to sales (P/S)
N/A
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
N/A
Earnings
Revenue
$0
EBIT
-$114.58M
EBITDA
-$114.45M
Free cash flow
-$10.28M
Per share
EPS
-$0.85
Free cash flow per share
-$0.07
Book value per share
$0.66
Revenue per share
$0
TBVPS
$0.02
Balance sheet
Total assets
$121.83M
Total liabilities
$23.75M
Debt
$3.82M
Equity
$98.09M
Working capital
-$21.09M
Liquidity
Debt to equity
0.04
Current ratio
0.08
Quick ratio
0.06
Net debt/EBITDA
-0.03
Margins
EBITDA margin
N/A
Gross margin
N/A
Net margin
N/A
Operating margin
N/A
Efficiency
Return on assets
-88.8%
Return on equity
-113.4%
Return on invested capital
N/A
Return on capital employed
-116%
Return on sales
N/A
Dividend
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A

RENB stock price

How has the Renovaro Biosciences stock price performed over time
Intraday
22.92%
1 week
134%
1 month
183.02%
1 year
-47.32%
YTD
-44.16%
QTD
266.23%

Financial performance

How have Renovaro Biosciences's revenue and profit performed over time
Revenue
$0
Gross profit
$0
Operating income
-$126.09M
Net income
-$115.69M
Gross margin
N/A
Net margin
N/A
Renovaro Biosciences's net income has plunged by 181% YoY and by 43% from the previous quarter
RENB's operating income has shrunk by 54% QoQ

Growth

What is Renovaro Biosciences's growth rate over time

Valuation

What is Renovaro Biosciences stock price valuation
P/E
N/A
P/B
2.66
P/S
N/A
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
N/A
The company's EPS fell by 20% YoY
The equity has surged by 110% year-on-year but it has declined by 26% since the previous quarter
The stock's P/B is 48% above its 5-year quarterly average of 1.8 and 2.3% above its last 4 quarters average of 2.6

Efficiency

How efficient is Renovaro Biosciences business performance
RENB's ROE has dropped by 56% year-on-year and by 25% since the previous quarter
The ROA has contracted by 48% YoY and by 26% from the previous quarter

Dividends

What is RENB's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for RENB.

Financial health

How did Renovaro Biosciences financials performed over time
The company's total liabilities has surged by 120% YoY but it fell by 24% QoQ
RENB's total assets has soared by 112% YoY but it is down by 25% QoQ
The debt is 96% smaller than the equity
The equity has surged by 110% year-on-year but it has declined by 26% since the previous quarter
The debt to equity has dropped by 60% year-on-year but it has increased by 33% since the previous quarter

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified. Data from and Sharadar.